Application of the Fc fusion format to generate tag-free bi-specific diabodies

FEBS Journal

Volumn 277, Issue 2, 2010, Pages 477-487

  Asano, Ryutaro ^a   Ikoma, Keiko ^a   Kawaguchi, Hiroko ^a   Ishiyama, Yuna ^a   Nakanishi, Takeshi ^a   Umetsu, Mitsuo ^a   Hayashi, Hiroki ^b   Katayose, Yu ^b   Unno, Michiaki ^b   Kudo, Toshio ^a   Kumagai, Izumi ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bi specific diabody; Fc fusion format; Preparation method; Small therapeutic antibody; Tag free protein

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; PAPAIN; PROTEINASE; RECOMBINANT ANTIBODY;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ARTICLE; CANCER INHIBITION; CELL LINE; GENE EXPRESSION SYSTEM; HUMAN RHINOVIRUS; INDUSTRY; MAMMAL; MASS SPECTROMETRY; METHODOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PURIFICATION; RECOGNITION;

ANIMALS; ANTIBODIES, BISPECIFIC; CELL LINE, TUMOR; CHO CELLS; CHROMATOGRAPHY, AFFINITY; CRICETINAE; CRICETULUS; GENE EXPRESSION; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOTHERAPY; NEOPLASMS; PEPTIDE HYDROLASES; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; RHINOVIRUS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

BACTERIA (MICROORGANISMS); CRICETULUS GRISEUS; HUMAN RHINOVIRUS 3; MAMMALIA;

EID: 74549223088     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2009.07499.x     Document Type: Article

References (39)

1. Cao Y Lam L (2003) Bispecific antibody conjugates in therapeutics. Adv Drug Deliv Rev 55, 171 197.
2. Kufer P, Lutterbuse R Baeuerle PA (2004) A revival of bispecific antibodies. Trends Biotechnol 22, 238 244.
3. Koelemij R, Kuppen PJ, van de Velde CJ, Fleuren GJ, Hagenaars M Eggermont AM (1999) Bispecific antibodies in cancer therapy, from the laboratory to the clinic. J Immunother 22, 514 524.
4. Segal DM, Weiner GJ Weiner LM (1999) Bispecific antibodies in cancer therapy. Curr Opin Immunol 11, 558 562.
5. van Spriel AB, van Ojik HH van De Winkel JG (2000) Immunotherapeutic perspective for bispecific antibodies. Immunol Today 21, 391 397.
6. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, Lee T, Pope SH, Riordan GS Whitlow M (1988) Single-chain antigen-binding proteins. Science 242, 423 426.
7. Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotny J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R et al. (1988) Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 85, 5879 5883.
8. Holliger P, Prospero T Winter G (1993) 'Diabodies': small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 90, 6444 6448.
9. Schlereth B, Fichtner I, Lorenczewski G, Kleindienst P, Brischwein K, da Silva A, Kufer P, Lutterbuese R, Junghahn I, Kasimir-Bauer S et al. (2005) Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3- bispecific antibody construct. Cancer Res 65, 2882 2889.
10. Arndt MA, Krauss J, Kipriyanov SM, Pfreundschuh M Little M (1999) A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors. Blood 94, 2562 2568.
11. Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D Weiner LM (2004) Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem 279, 53907 53914.
12. Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, Gonzalez Trotter DE Adams GP (2005) Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res 65, 1471 1478.
13. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 44, 1962 1969.
14. Kipriyanov SM, Moldenhauer G, Schuhmacher J, Cochlovius B, Von der Lieth CW, Matys ER Little M (1999) Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol 293, 41 56.
15. Le Gall F, Reusch U, Little M Kipriyanov SM (2004) Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody. Protein Eng Des Sel 17, 357 366.
16. Peipp M Valerius T (2002) Bispecific antibodies targeting cancer cells. Biochem Soc Trans 30, 507 511.
17. Helfrich W, Kroesen BJ, Roovers RC, Westers L, Molema G, Hoogenboom HR de Leij L (1998) Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas. Int J Cancer 76, 232 239.
18. Tsumoto K, Shinoki K, Kondo H, Uchikawa M, Juji T Kumagai I (1998) Highly efficient recovery of functional single-chain Fv fragments from inclusion bodies overexpressed in Escherichia coli by controlled introduction of oxidizing reagent - application to a human single-chain Fv fragment. J Immunol Methods 219, 119 129.
19. Skerra A Schmidt TG (2000) Use of the Strep-Tag and streptavidin for detection and purification of recombinant proteins. Methods Enzymol 326, 271 304.
20. Asano R, Sone Y, Makabe K, Tsumoto K, Hayashi H, Katayose Y, Unno M, Kudo T Kumagai I (2006) Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent. Clin Cancer Res 12, 4036 4042.
21. Asano R, Kawaguchi H, Watanabe Y, Nakanishi T, Umetsu M, Hayashi H, Katayose Y, Unno M, Kudo T Kumagai I (2008) Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells. J Immunother 31, 752 761.
22. Asano R, Sone Y, Ikoma K, Hayashi H, Nakanishi T, Umetsu M, Katayose Y, Unno M, Kudo T Kumagai I (2008) Preferential heterodimerization of a bispecific diabody based on a humanized anti-EGFR antibody 528. Protein Eng Des Sel 21, 597 603.
23. Presta L (2003) Antibody engineering for therapeutics. Curr Opin Struct Biol 13, 519 525.
24. Kontermann RE (2005) Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol Sin 26, 1 9.
25. Marvin JS Zhu Z (2005) Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol Sin 26, 649 658.
26. Carter P (2001) Bispecific human IgG by design. J Immunol Methods 248, 7 15.
27. Asano R, Watanabe Y, Kawaguchi H, Fukazawa H, Nakanishi T, Umetsu M, Hayashi H, Katayose Y, Unno M, Kudo T et al. (2007) Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells. J Biol Chem 282, 27659 27665.
28. Perisic O, Webb PA, Holliger P, Winter G Williams RL (1994) Crystal structure of a diabody, a bivalent antibody fragment. Structure 2, 1217 1226.
29. Asano R, Kudo T, Nishimura Y, Makabe K, Hayashi H, Suzuki M, Tsumoto K Kumagai I (2002) Efficient construction of a diabody using a refolding system: anti-carcinoembryonic antigen recombinant antibody fragment. J Biochem 132, 903 909.
30. Alt M, Muller R Kontermann RE (1999) Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region. FEBS Lett 454, 90 94.
31. Wu AM, Tan GJ, Sherman MA, Clarke P, Olafsen T, Forman SJ Raubitschek AA (2001) Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange. Protein Eng 14, 1025 1033.
32. Goel A, Beresford GW, Colcher D, Pavlinkova G, Booth BJ, Baranowska-Kortylewicz J Batra SK (2000) Divalent forms of CC49 single-chain antibody constructs in Pichia pastoris: expression, purification, and characterization. J Biochem 127, 829 836.
33. Brusselbach S, Korn T, Volkel T, Muller R Kontermann RE (1999) Enzyme recruitment and tumor cell killing in vitro by a secreted bispecific single-chain diabody. Tumor Target 4, 115 123.
34. Kipriyanov SM, Moldenhauer G, Braunagel M, Reusch U, Cochlovius B, Le Gall F, Kouprianova OA, Von der Lieth CW Little M (2003) Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies. J Mol Biol 330, 99 111.
35. Korn T, Nettelbeck DM, Volkel T, Muller R Kontermann RE (2004) Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv. J Gene Med 6, 642 651.
36. K genes of an anti-CD3 monoclonal antibody, and construction of a mouse/human chimeric antibody. J Biochem 120, 657 662.
37. Umetsu M, Tsumoto K, Hara M, Ashish K, Goda S, Adschiri T Kumagai I (2003) How additives influence the refolding of immunoglobulin-folded proteins in a stepwise dialysis system. Spectroscopic evidence for highly efficient refolding of a single-chain Fv fragment. J Biol Chem 278, 8979 8987.
38. Hayashi H, Asano R, Tsumoto K, Katayose Y, Suzuki M, Unno M, Kodama H, Takemura S, Yoshida H, Makabe K et al. (2004) A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells. Cancer Immunol Immunother 53, 497 509.
39. Asano R, Kudo T, Makabe K, Tsumoto K Kumagai I (2002) Antitumor activity of interleukin-21 prepared by novel refolding procedure from inclusion bodies expressed in Escherichia coli. FEBS Lett 528, 70 76.